Stem Cell Manufacturing Market Research Report - Forecast to 2030

Stem Cell Manufacturing Market Research Report Information by Product (Stem Cell Lines [Mesenchymal Stem Cells (MSCs), Induced Pluripotent Stem Cell (iPSC), Embryonic Stem Cell (ESC), Hematopoietic Stem Cells (HSCs), and Others], Instruments [Bioreactors, Incubators, Cell Sorters, and Others], Culture Media, and Consumables), by Application (Research, Target Identification, Stem Cell-Based Therapy [Autologous and Allogeneic], and Cell & Tissue Banking), by End User (Pharmaceutical & Biotechnology Companies, Hospitals, Stem Cell Banks, and O

ID: MRFR/LS/5477-CR | 116 Pages | Published By Kinjoll Dey on March 2023         

Stem Cell Manufacturing Market Speak to Analyst Request a Free Sample

Global Stem Cell Manufacturing Market Overview


Stem Cell Manufacturing Market Size was valued at USD 10.64 billion in 2021. The Stem Cell Manufacturing Market industry is projected to grow from USD 12.02 billion in 2022 to USD 32.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 13.16% during the forecast period (2022 - 2030). The driving factors that are boosting market growth are growing awareness regarding the usage of stem cells for treating various diseases and the increasing prevalence of rare diseases.
Stem Cell Manufacturing Market Overview
Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Stem Cell Manufacturing Market Trends



  • Growing awareness regarding the usage of stem cells for treating various diseases boosts market growth


Stem cells help treat a wide range of incurable diseases such as acquired immune deficiency syndrome (AIDS), for which the treatments were previously unknown. Stem cell therapy also helps treat cardiovascular diseases, neurodegenerative diseases, autoimmune diseases, orthopedic conditions, and healing incisions & wounds. They are increasingly being utilized for replacing damaged neurons caused by spinal cord injuries, Parkinson's disease, Alzheimer's disease, and other neurological problems. They also produce insulin that supports in treatment of patients with diabetes and weak heart muscle and replaces the damaged tissue or the injured or diseased organ.


Moreover, rare diseases affect a small percentage of the population and are often neglected conditions whose treatments are often not considered profitable due to their cost to develop and limited patient population. Rare diseases include rare cancers, genetic diseases, infectious tropical diseases, and degenerative diseases. According to the data published by Food and Drug Administration (FDA) in February 2020, there were around 7,000 rare diseases, more than half of which affect children, and only 5% have FDA-approved treatments. Hence, increasing awareness associated with the usage of stem cells in treatment of various diseases and rising incidences of rare diseases propelling the growth of the market.


Stem Cell Manufacturing Market Segment Insights


Stem Cell Manufacturing Product Insights


The Stem Cell Manufacturing Market segmentation, based on product, includes stem cell lines, instruments, culture media, and consumables. The stem cell lines segmented into mesenchymal stem cells (MSCs), induced pluripotent stem cell (iPSC), embryonic stem cell (ESC), hematopoietic stem cells (HSCs), and others moreover, instruments further segmented into bioreactors, incubators, cell sorters, and others. The stem cell lines segment accounted for the largest market share in 2021. The advent of stem cell research unveiled the therapeutic potential of stem cells and their derivatives and increased the awareness of the same in the public and scientific community. The successful manufacturing of stem cells and their derivatives has positively impacted medical sciences owing to its ever-expanding therapeutic solutions for patients is boosting the segment growth during the forecast period.


April 2021 Bristol-Myers Squibb Company (US) expands its business by building a new cell therapy manufacturing unit in the Netherlands. This expansion has given Bristol new opportunities.


Stem Cell Manufacturing Application Insights


The Stem Cell Manufacturing Market data has been segmented, based on application, by research, target identification, stem cell-based therapy, and cell & tissue banking. The stem cell-based therapy segment was anticipated to reach USD 4.84 billion by 2021. The stem cell based further bifurcated into autologous and allogeneic. Autologous stem cell therapy provides high compatibility with the human immune system, as the patients are their own donors of stem cells. For instance, in March 2021, Novadip Biosciences (Belgium) received approval from US FDA for the company’s Investigational New Drug (IND) application for its autologous cell therapy product NVD-003. Therefore, strategic alliances are propelling the growth of the segment.


October 2021 Bristol-Myers Squibb Company (US) announced positive topline results from phase 3 transform trial evaluating breyanzi versus chemotherapy followed by stem cell transplant in second-line relapsed or refractory large b-cell lymphoma.


Figure 2 Stem Cell Manufacturing Market, by Application, 2021 & 2030 (USD Billion)
Stem Cell Manufacturing Market, by Application, 2021 & 2030
Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Stem Cell Manufacturing End User Insights


Based on end user, the global stem cell market is segmented into hospitals, pharmaceutical, and biotechnology companies, stem cell banks, and others. The pharmaceutical, and biotechnology companies accounted for the largest market share in 2021. Pharmaceutical & biotechnology companies have taken an increased interest in stem cell biology. The use of stem cells as research tools has expanded, with most major pharmaceutical companies using embryonic stem cells (ESCs) or adult stem cells for internal drug discovery programs. These internal efforts are often enhanced through the expertise of external partnerships with academics or biotech companies which is bolstering the growth of the segment.


Stem Cell Manufacturing Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America stem cell manufacturing market accounted for the largest market share in 2021, due to increasing prevalence of chronic diseases such as cancer, cardiovascular disorders, neurological disorders, gastrointestinal diseases, other chronic conditions. In 2020, as per the National Cancer Institute, the National Institutes of Health forecasted an estimated 1,806,590 new cases of cancer to be diagnosed in the US, with about 606,520 deaths reported as a result of the disease.


Further, the major countries studied are The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3 STEM CELL MANUFACTURING MARKET, BY REGION 2021 & 2030 (USD Billion)
STEM CELL MANUFACTURING MARKET, BY REGION 2021 & 2030
Source Secondary Research, Primary Research, MRFR Database and Analyst Review


Europe stem cell manufacturing market accounts for the second-largest market share due to the accessibility to advanced treatment facilities, support by government bodies for the development of the healthcare sector, the rising geriatric population, and the growing number of cases suffering from chronic and neurological disorders. Furthermore, the Germany stem cell manufacturing market held the largest market share in 2021, and the UK stem cell manufacturing market was the fastest growing market in the Europe region.


The Asia-Pacific stem cell manufacturing market is expected to grow at a significant share from 2022 to 2030 due to the factors such as improving healthcare infrastructure, growing adoption of stem cell therapy treatments, availability of contract manufacturers, and rising prevalence of cancer in the region, which are likely to drive the market’s growth. Moreover, China stem cell manufacturing market held the largest market share, and the India stem cell manufacturing market was the fastest growing market in the Asia-Pacific region.


Stem Cell Manufacturing Key Market Players & Competitive Insights


Major market players are spending a lot of money on R&D to increase their product lines, which will help the stem cell manufacturing market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations. Competitors in the stem cell manufacturing industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.


Fujifilm Holdings Corporation (US) is the holding company of the Fujifilm Group, whose main business is in photographic films. Fujifilm has three operating companies headquartered in Japan Fuji Xerox Co., Ltd, FUJIFILM Corporation, and Toyama Chemical Co., Ltd. In January 2022, the company acquired a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (US), a leading allogeneic T-cell immunotherapy company, for USD 100 million. This acquisition is helping to Fujifilm Holdings Corporation (US) to expand its biosciences business.


Key Companies in the Stem Cell Manufacturing Market includes.


 



  • Fujifilm Holdings Corporation (US)

  • AbbVie, Inc. (US)

  • Bio-Rad Laboratories, Inc. (US)

  • Becton, Dickinson, and Company (US)

  • Thermo Fisher Scientific, Inc. (US)

  • Lonza Group (Switzerland)

  • Bristol-Myers Squibb Company (US)

  • GlaxoSmithKline Plc (UK)

  • Sartorius AG (Germany)

  • Merck KGaA (Germany)

  • Others


 


Stem Cell Manufacturing Industry Developments


January 2022 Thermo Fisher Scientific Inc. (US) acquired PeproTech, Inc., (US), with a total cash purchase price of USD1,850 million. Cell & gene therapies and other cell culture applications utilize recombinant proteins in their development and manufacture.


March 2021 Fujifilm Holdings Corporation (US) contract development and manufacturing organization (CDMO), the US-based subsidiary, and Fujifilm Diosynth Biotechnologies (US) expanded its new manufacturing site with USD 2000 million cell culture facility in the North America region.


July 2020 Thermo Fisher Scientific Inc. (US) and Lyell Immunopharma (US) partnered to develop manufacturing procedures that resulted in more effective cell treatments for cancer patients. The company's major purpose is to improve T cell fitness and gain access to and knowledge of developing technologies.


Stem Cell Manufacturing Market Segmentation


Stem Cell Manufacturing Product Outlook


 



  • Stem Cell Lines

    • Mesenchymal Stem Cells (MSCs)

    • Induced Pluripotent Stem Cell (iPSC)

    • Embryonic Stem Cell (ESC)

    • Hematopoietic Stem Cells (HSCs)

    • Others



  • Instruments

    • Bioreactors

    • Incubators

    • Cell Sorters

    • Others



  • Culture Media

  • Consumables


 


Stem Cell Manufacturing Application Outlook


 



  • Research

  • Target Identification

  • Stem Cell-Based Therapy

    • Autologous

    • Allogenic



  • Cell & Tissue Banking


 


Stem Cell Manufacturing End User Outlook


 



  • Pharmaceutical & Biotechnology Companies

  • Hospitals

  • Stem Cell Banks

  • Others


 


Stem Cell Manufacturing Regional Outlook




  • North America



    • US

    • Canada


     




  • Europe



    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe


     




  • Asia-Pacific



    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Rest of Asia-Pacific


     




  • Rest of the World




    • Middle East




    • Africa




    • Latin America







Report Scope:

Report Attribute/Metric Details
Market Size 2021 USD 10.64 billion
Market Size 2022 USD 12.02 billion
Market Size 2030 USD 32.39 billion
Compound Annual Growth Rate (CAGR) 13.16% (2022-2030)
Base Year 2021
Forecast Period 2022-2030
Historical Data 2018 & 2020
Forecast Units Value (USD Billion)
Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered Product, Application, End User, and Region
Geographies Covered North America, Europe, Asia Pacific, and Rest of the World
Countries Covered The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled Fujifilm Holdings Corporation (US), AbbVie, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), Lonza Group (Switzerland), Bristol-Myers Squibb Company (US), GlaxoSmithKline Plc (UK), Sartorius AG (Germany), Merck KGaA (Germany) and Others
Key Market Opportunities Increasing public and private funding for stem cell-based research
Key Market Drivers Growing awareness regarding the usage of stem cells for treating various diseases Increasing prevalence of rare diseases


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The Stem Cell Manufacturing Market is anticipated to reach 32.39 billion at a CAGR of 13.16% during the forecast period of 2022-2030.

The US is expected to hold a 85.80% share of the global market for stem cell manufacturing market during the forecast period of 2022-2030.

The stem cell manufacturing market is expected to grow at a 13.16% CAGR during the forecast period from 2022 to 2030.

The North America region market held the largest market share in stem cell manufacturing market.

The key players include Fujifilm Holdings Corporation (US), AbbVie, Inc. (US), Bio-Rad Laboratories, Inc. (US), Becton, Dickinson and Company (US), Thermo Fisher Scientific, Inc. (US), Lonza Group (Switzerland), Bristol-Myers Squibb Company (US), GlaxoSmithKline Plc (UK), Sartorius AG (Germany), Merck KGaA (Germany) and Others.

The stem cell lines product led the stem cell manufacturing market.

Stem cell-based therapy application segment had the largest market share.